Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Hims & Hers Health, Inc. (HIMS) vs Indivior Pharmaceuticals Inc. (INDV)

Hims & Hers Health, Inc. and Indivior Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Hims & Hers Health, Inc. is the larger, with a market value of $6.9B against $4.3B — 1.6× the size. Hims & Hers Health, Inc. has negative trailing earnings, so its P/E is not meaningful; Indivior Pharmaceuticals Inc. trades at 12.4×. Hims & Hers Health, Inc. grew revenue faster over the last twelve months: 28.0% against 13.5%. Indivior Pharmaceuticals Inc. has the higher net margin (26.8% vs −5.51%) and the higher return on invested capital (460.5% vs −11.4%). Across the 17 metrics below, Indivior Pharmaceuticals Inc. leads on 9 and Hims & Hers Health, Inc. on 8.

Valuation

Metric HIMS INDV Drug Manufacturers Specialty & Generic median
P/E n/m 12.40 20.14
P/S 2.65 3.20 2.25
P/B 21.07 n/m 1.90
Price to free cash flow 82.23 n/m 16.54
EV/EBITDA n/m 10.43 12.29
EV/Sales 2.85 3.42 2.56
Earnings yield (2.07%) 8.07% (2.99%)
Free cash flow yield 1.22% (2.65%) 0.00%

Profitability

Metric HIMS INDV Drug Manufacturers Specialty & Generic median
Gross margin 68.43% 81.97% 53.94%
Operating margin (5.99%) 31.56% 0.00%
Net margin (5.51%) 26.75% 0.00%
Free cash flow margin 3.22% (8.34%) 0.00%
Return on equity (32.03%) (153.12%) (0.40%)
Return on assets (5.16%) 26.52% (3.32%)
Return on invested capital (11.38%) 460.53% 0.00%

Growth

Metric HIMS INDV Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 28.04% 13.47% 10.01%
EPS growth (last fiscal year) (3.77%) 3,017.87% —
Revenue growth, 5-year CAGR 53.90% 13.88% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HIMS INDV Drug Manufacturers Specialty & Generic median
Debt to equity 4.21 (2.34) 0.05
Current ratio 0.93 0.84 2.31
Net debt to EBITDA 2.43 0.44 0.85

Dividend

Metric HIMS INDV Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 — 0.00

Size

Metric HIMS INDV Drug Manufacturers Specialty & Generic median
Market cap 6.87b 4.25b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack